Product Reports Resources Pricing Login Book a demo

Vividion Therapeutics

Biotech & Life Sciences · San Diego, United States · Founded 2014

Vividion Therapeutics is a biopharmaceutical company that operates as a wholly owned and independently operated subsidiary of Bayer AG. The company focuses on the development of small-molecule therapeutics for oncology and immunology indications. Its proprietary chemoproteomic platform technology allows for the identification of previously unknown, or "undruggable," protein targets, enabling the discovery of novel drugs. The company's business model is centered on research and development, with a pipeline of candidates in various stages of preclinical and clinical development. Vividion collaborates with its parent company, Bayer, to advance its programs, benefiting from the larger company's resources and expertise while maintaining its operational independence. The company's revenue is primarily generated through milestone payments and royalties from its collaboration and licensing agreements. Keywords: biopharmaceutical, small-molecule therapeutics, oncology, immunology, chemoproteomics, drug discovery, protein targets, clinical development, preclinical, licensing agreements

Valuation $1–2.5B
Revenue $10–50M
Headcount 100–500
Total funding $100–500M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Vividion Therapeutics and the history behind them.
Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Investors

23 investors on Vividion Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage
Cardinal Partners
ARCH Venture Partners
Versant Ventures
Nextech Invest
Casdin Capital
Altitude Life Science Ventures
Trinitas Capital
Series B+ 16 investors entered at this stage
Bristol-Myers Squibb
Celgene
Tavistock Group
Logos Capital
Driehaus Capital Management
Acuta Capital Partners
T. Rowe Price
Avoro Capital Advisors
Mubadala Capital
BVF Partners
Citadel
RA Capital Management
Boxer Capital
BlackRock
SoftBank
Woodline Partners

Global footprint

Where Vividion Therapeutics has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States98.7%
🇩🇪 Germany0.8%
🇦🇪 United Arab Emirates0.4%
3 countries shown
Web traffic by country
7.2K monthly visits
across markets
🇺🇸 United States81.9%
🇮🇳 India15.3%
🇩🇪 Germany4.2%
Top 3 markets shown

Talent graph

The shape of Vividion Therapeutics's talent

Dealroom maps Vividion Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 standout operatorsDealroom-flagged across the org
2 AI specialistsincl. 1 core researchers
268 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Vividion Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$1M patent portfolio · 17 active families

Estimated portfolio value
$1M
0.09% of valuation · 127.5× smaller than top peer PTC Therapeutics ($168M)
17 active patent families
Where Vividion Therapeutics innovates BiochemistryCancer researchCarcinosisCell biologyDepressant

Where Vividion Therapeutics concentrates vs peers

Each axis is a top-10 topic across Vividion Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Vividion Therapeutics

An AI-synthesized read of the highest-engagement posts about Vividion Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vividion Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles